[go: up one dir, main page]

AR056265A1 - N-aminometilensulfonamidas sustituidas, su preparacion y su uso como medicamentos - Google Patents

N-aminometilensulfonamidas sustituidas, su preparacion y su uso como medicamentos

Info

Publication number
AR056265A1
AR056265A1 ARP060100169A ARP060100169A AR056265A1 AR 056265 A1 AR056265 A1 AR 056265A1 AR P060100169 A ARP060100169 A AR P060100169A AR P060100169 A ARP060100169 A AR P060100169A AR 056265 A1 AR056265 A1 AR 056265A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
heterocyclyl
heteroaryl
alkoxy
Prior art date
Application number
ARP060100169A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR056265A1 publication Critical patent/AR056265A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/32—Nitrogen atoms acylated with carboxylic or carbonic acids, or their nitrogen or sulfur analogues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Reivindicacion 1: Compuesto de la formula (1), caracterizado porque: R1 es hidrogeno, halogeno o -CF3; R2 es hidrogeno, -NH2, -NH(alquilo C1-3), -N(alquilo C1-3)2 o alcoxi C1-3 y Rl y R2 no pueden ser al mismo tiempo hidrogeno; R3 es alquilo C1-10 no sustituido o al menos monosustituido, alquenilo C2-10, arilo, heterociclilo o heteroarilo, en donde los sustituyentes están seleccionados del grupo compuesto por: arilo, heteroarilo, heterociclilo, arilo-(alquilo C1-6)-, heterociclil-(alquilo C1- 6)-, heteroaril-(alquilo C1-6)-, -O-arilo, fluor, cloro, bromo, -CF3, -OCF3, -NO2, -CN, -C(O)R7, hidroxi, alquilo C1-6 y alcoxi C1-3, y los fragmentos de arilo, heteroarilo y heterociclilo de estos sustituyentes pueden estar al menos monosustituidos, a su vez, con fluor, cloro, bromo, oxo, -CF3, -OCF3, -NO2, -CN, hidroxi, alquilo C1-3 o alcoxi C1-3; R4 y R5 son, de modo independiente entre sí, hidrogeno, alquilo C1-10 o aril-(alquilo C1-6)- no sustituido o al menos sustituido; en donde los sustituyentes están seleccionados del grupo compuesto por: arilo, heteroarilo, heterociclilo, aril-(alquilo C1-6)-, heterociclil-alquiloC1-6)-, heteroaril-(alquilo C1-6)-, -O-arilo, fluor, cloro, bromo, -CF3, -OCF3, -NO2, -CN, -C(O)R7, hidroxi, alquilo C1-6 y alcoxi C1-3, y los fragmentos de arilo, heteroarilo y heterociclilo de estos sustituyentes pueden estar al menos monosustituidos, a su vez, con fluor, cloro, bromo, oxo, -CF3, -OCF3, -NO2, -CN, hidroxi, alquilo C1-3 o alcoxi C1-3; o R4 y R5 forman junto con el átomo de nitrogeno al que están unidos heterociclilo no sustituido o al menos monosustituido; en donde los sustituyentes están seleccionados de: halogeno, alquilo C1-6, alcoxi C1-6, fenilo, oxo, -NH2, -NH(alquilo C1-3), -N(alquilo C1-3)2, -OCF3, -CF3 o hidroxi; R6 es hidrogeno, -SO2(alquilo C1-3), alquilo C1-10 no sustituido o al menos monosustituido, alquenilo C2-10 o aril-(alquilo C1-6)-, en donde los sustituyentes están seleccionados de: halogeno, alquilo C1-6, alcoxi C1-6, fenilo, oxo, -NH2, -NH(alquilo C1-3), -N(alquiloC1-3)2, -OCF3, -CF3 o hidroxi; o R6 forman junto con R3 y X, siempre que X sea igual a N, heterociclilo no sustituido o al menos monosustituido, en donde los sustituyentes están seleccionados del grupo compuesto por: arilo, heteroarilo, heterociclilo, aril-(alquilo C1-6)-, heterociclil-(alquiloC1-6)-, heteroaril-(alquiloC1-6)-, -O-arilo, fluor, cloro, bromo, -CF3, -OCF3, -NO2, -CN, -C(O)R7, hidroxi, C1-C6 y alcoxi C1-3, y los fragmentos de arilo, heteroarilo y heterociclilo de estos sustituyentes pueden estar al menos monosustituidos, a su vez, con fluor, cloro, bromo, oxo, -CF3, -OCF3, -NO2, -CN, hidroxi, alquilo C1-3 o alcoxi C1-3; R7 es alcoxi C1-3, -O-fenilo, alquilo C1-3, -NH2, NH(alquiloC1-3), -N(alquiloC1-3)2 o fenilo, y los fragmentos de fenilo de R7 pueden estar, a su vez, al menos monosustituidos con fluor, cloro, bromo, -CF3, -OCF3, -NO2, -CN, hidroxi, alquilo C1-3 o alcoxi C1-3; A es SO2, CO o CH2; X es NR6 u O; heteroarilo es un heterociclo mono- o bicíclico aromático de 5 a 10 miembros, que contiene uno o varios heteroátomos seleccionados de N, O y S; arilo es un mono- o biciclo aromático de 5 a 10 miembros; heteroarilo es un heterociclilo mono- o bicíclico no aromático de 5 a 10 miembros, que contiene uno o varios heteroátomos seleccionados de N, O y S; o una de sus sales fisiologicamente tolerables; con la condicion de que, cuando R2 es hidrogeno y R1 es halogeno, -A- XR3 no sea: i) -C(O)-O-CH2-CH2-NH2, ii) -C(O)-NH-CH2-CH=CH2, iii) -C(O)-NH-CH2-CH2-Z, con Z igual a halogeno, hidroxi, trialquilamino, mesilato o tosilato, iv) -C(O)-O-(alquilo C1-6), v) -C(O)-NH-bencimidazolilo o vi) -C(O)-NH-(1,2,3,4- tetrahidroisoquinolinilo), en donde en: i) y iii) el fragmento de -CH2-CH2- puede presentar 1 a 4 radicales alquilo R1 a R4 radicales alquilo R1 a R4 cada uno con C1-4, en donde uno de los radicales R1 a R4 también puede significar un grupo carboxi, hidroximetilo o alquiloxicarbonilo con 5 átomos de carbono como máximo o uno o dos de los radicales R1 a R4 pueden significar isopropilo, isobutilo, tert.-butilo, fenilo o cicloalquilo C5-6, y en donde v) y vi) el fragmento de bencimidazolilo y de (1,2,3,4-tetrahidroisoquinolinilo) pueden no ser sustituidos o al menos monosustituidos.
ARP060100169A 2005-01-17 2006-01-16 N-aminometilensulfonamidas sustituidas, su preparacion y su uso como medicamentos AR056265A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005002130A DE102005002130A1 (de) 2005-01-17 2005-01-17 Substituierte N-Aminomethylensulfonamide, ihre Herstellung und Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
AR056265A1 true AR056265A1 (es) 2007-10-03

Family

ID=36650366

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100169A AR056265A1 (es) 2005-01-17 2006-01-16 N-aminometilensulfonamidas sustituidas, su preparacion y su uso como medicamentos

Country Status (15)

Country Link
US (1) US7781613B2 (es)
EP (1) EP1841731B1 (es)
JP (1) JP2008526914A (es)
KR (1) KR20070094789A (es)
CN (1) CN101107222A (es)
AR (1) AR056265A1 (es)
AU (1) AU2006205823A1 (es)
BR (1) BRPI0606326A2 (es)
CA (1) CA2601343A1 (es)
DE (1) DE102005002130A1 (es)
IL (1) IL184526A0 (es)
MX (1) MX2007008611A (es)
TW (1) TW200637810A (es)
UY (1) UY29337A1 (es)
WO (1) WO2006074957A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090047458A (ko) 2006-08-08 2009-05-12 사노피-아벤티스 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
CN104502513B (zh) * 2015-01-14 2016-04-06 中国矿业大学连云港徐圩新区高新技术研究院 一种对羧基苯磺酰胺的高效液相色谱测定方法
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
US11203597B2 (en) 2018-11-14 2021-12-21 Altavant Sciences Gmbh Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3009910A (en) 1960-01-04 1961-11-21 Merck & Co Inc 2, 4-disulfamyl-aniline derivatives
DE2419970C3 (de) * 1974-04-25 1980-06-12 Hoechst Ag, 6000 Frankfurt 3-<l-Pyrrolidinyl)-4-phenoxy-5sulfamoylbenzoesäure und Verfahren zu ihrer Herstellung
DE2518999A1 (de) * 1975-04-29 1976-11-18 Hoechst Ag Verfahren zur herstellung von sulfamylbenzoesaeuren
DE2836085A1 (de) 1978-08-17 1980-03-06 Hoechst Ag Sulfamoylbenzolderivate und verfahren zu ihrer herstellung
HU207051B (en) * 1987-12-30 1993-03-01 Chinoin Gyogyszer Es Vegyeszet Process for producing 4-chloro-3-sulfamoylbenzoic acid hydrazides and pharmaceutical compositions comprising such compounds
HU198458B (en) * 1987-12-30 1989-10-30 Chinoin Gyogyszer Es Vegyeszet Process for producing 2-aminoisoquinoline derivatives and pharmaceutical compositions comprising these compounds
EP1458374A2 (en) 2001-12-14 2004-09-22 Novo Nordisk A/S Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
AU2003223930A1 (en) 2002-06-14 2003-12-31 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
DE10247680B4 (de) 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase

Also Published As

Publication number Publication date
EP1841731A1 (de) 2007-10-10
TW200637810A (en) 2006-11-01
US7781613B2 (en) 2010-08-24
EP1841731B1 (de) 2012-08-22
CN101107222A (zh) 2008-01-16
AU2006205823A1 (en) 2006-07-20
US20080069851A1 (en) 2008-03-20
UY29337A1 (es) 2006-08-31
IL184526A0 (en) 2007-10-31
BRPI0606326A2 (pt) 2009-06-16
KR20070094789A (ko) 2007-09-21
CA2601343A1 (en) 2006-07-20
WO2006074957A1 (de) 2006-07-20
JP2008526914A (ja) 2008-07-24
MX2007008611A (es) 2008-01-14
DE102005002130A1 (de) 2006-07-27
WO2006074957A9 (de) 2007-07-12

Similar Documents

Publication Publication Date Title
AR056265A1 (es) N-aminometilensulfonamidas sustituidas, su preparacion y su uso como medicamentos
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR110051A2 (es) Pirazolo[3,4-d]pirimidinas útiles para tratar trastornos respiratorios
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
AR078786A1 (es) Derivados de la cromenona
PE20212302A1 (es) Inhibidores de apol1 y sus metodos de uso
AR065795A1 (es) Derivados de aza-piridopirimidinona,metodo de preparacion,medicamentos que los contienen y usos como agentes antitromboticos, antihiperlipidemicos y antidiabeticos,entre otros.
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
CO6160307A2 (es) Compuestos de pirazolina y su uso y composiciones farmaceuticas
AR109958A1 (es) Lactamas bicíclicas de piridona y sus métodos de uso
ES2630079T3 (es) Moduladores de la ruta del complemento y usos de los mismos
AR068503A1 (es) Derivados de amidas sustituidas, composicion farmaceutica y usos.
AR059571A1 (es) Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas
AR060535A1 (es) Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina
AR086144A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
AR082633A1 (es) Analogos de tetraciclina
AR066492A1 (es) Derivados de imidazoquinolina, proceso para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de enfermedades virales, bacterianas, alergicas y distintos tipos de canceres.
RU2014129742A (ru) Производные бензолсульфонамида в качестве модуляторов rorc
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
AR062409A1 (es) Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto
AR099498A1 (es) Compuestos de triazina y su uso farmacéutico
AR065587A1 (es) Aminoamidas como antagonistas de orexina
AR068466A1 (es) Cianoisoquinolina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal